These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31787982)

  • 1. Editorial: Nanoparticle Vaccines Against Infectious Diseases.
    Reljic R; González-Fernández Á
    Front Immunol; 2019; 10():2615. PubMed ID: 31787982
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanoparticle Vaccines Against Infectious Diseases.
    Pati R; Shevtsov M; Sonawane A
    Front Immunol; 2018; 9():2224. PubMed ID: 30337923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design.
    van Riet E; Ainai A; Suzuki T; Kersten G; Hasegawa H
    Adv Drug Deliv Rev; 2014 Jul; 74():28-34. PubMed ID: 24862579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease.
    Mortellaro A; Ricciardi-Castagnoli P
    Immunol Cell Biol; 2011 Mar; 89(3):332-9. PubMed ID: 21301476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoting life course vaccination.
    Michel JP; Lang PO
    Rejuvenation Res; 2011 Feb; 14(1):75-81. PubMed ID: 21208066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation technologies for oral vaccines.
    New RRC
    Clin Exp Immunol; 2019 Nov; 198(2):153-169. PubMed ID: 31318446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of vaccines and vaccinations: Challenges and opportunities for modelers.
    Curtiss R
    Math Biosci Eng; 2011 Jan; 8(1):77-93. PubMed ID: 21361401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New adjuvants for human vaccines.
    Mbow ML; De Gregorio E; Valiante NM; Rappuoli R
    Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next Generation Vaccines for Infectious Diseases.
    Sautto GA; Kirchenbaum GA; Diotti RA; Criscuolo E; Ferrara F
    J Immunol Res; 2019; 2019():5890962. PubMed ID: 31183388
    [No Abstract]   [Full Text] [Related]  

  • 10. Mucosal Vaccine Development Based on Liposome Technology.
    Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
    J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM; Klaschik S; Sato T; Tross D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan-based Nanoparticles in Mucosal Vaccine Delivery.
    Mehrabi M; Montazeri H; Mohamadpour Dounighi N; Rashti A; Vakili-Ghartavol R
    Arch Razi Inst; 2018 Sep; 73(3):165-176. PubMed ID: 30280836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The global challenge and future strategies for keeping the world's aging population healthy by vaccination.
    Steeper M; Plebanski M; Flanagan KL
    Trans R Soc Trop Med Hyg; 2016 Aug; 110(8):427-31. PubMed ID: 27618919
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccines work.
    Nat Commun; 2018 Apr; 9(1):1666. PubMed ID: 29691393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in assessment of vaccine on herd protection].
    Jin PF; Li JX; Zhu FC
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Jun; 39(6):862-866. PubMed ID: 29936762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for assessing cell-mediated immunity in infectious disease resistance and in the development of vaccines.
    Clough NE; Roth JA
    J Am Vet Med Assoc; 1995 Apr; 206(8):1208-16. PubMed ID: 7768746
    [No Abstract]   [Full Text] [Related]  

  • 17. Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
    Malik A; Gupta M; Mani R; Gogoi H; Bhatnagar R
    Front Immunol; 2018; 9():562. PubMed ID: 29616046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.
    Borges O; Tavares J; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
    Eur J Pharm Sci; 2007 Dec; 32(4-5):278-90. PubMed ID: 17884394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model.
    Sadati SF; Jamali A; Abdoli A; Abedi-Valugerdi M; Gholami S; Alipour S; Soleymani S; Kheiri MT; Atyabi F
    Pathog Dis; 2018 Nov; 76(8):. PubMed ID: 30184220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination, evolution and changes in the efficacy of vaccines: a theoretical framework.
    McLean AR
    Proc Biol Sci; 1995 Sep; 261(1362):389-93. PubMed ID: 8587880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.